Cytosorbents Corp · Stock award · Common Stock

What does this filing report?

An SEC Form 4 filing for Cytosorbents Corp records a stock award involving Common Stock on November 18, 2025. The reported quantity was 100,000. The filing date is November 20, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The transaction reported on this Form 4 reflects an open market purchase made by the reporting person.

F2

Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

F3

(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof;

F4

(continued from footnote 3) (iv) 105,600 RSUs which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and (v) 1,113,363 shares of Common Stock owned by the Reporting Person.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.